CK
Therapeutic Areas
Peter Biotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Gene Correction Programs | Metabolic Disorders, Sickle Cell Disease, Duchenne Muscular Dystrophy | Pre-clinical |
| Oncology Programs | Oncology (unspecified) | Pre-clinical |
Leadership Team at Peter Biotherapeutics
DH
Dirk Hondmann
Chief Executive Officer
YX
Yan Xiao
Senior Vice President, Discovery
GW
George Westerkamp
Board Member